Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (121-130 of 210) with videos related to

Pageof 21
Sort By:
Radiology|August 22, 2007
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experienceArpi Thukral, David M Thomasson, Catherine K Chow, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2022
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSandra M Swain, Antoinette R Tan, Luca Gianni, et al.
Journal of the National Cancer Institute|March 15, 2011
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCISIrene L Wapnir, James J Dignam, Bernard Fisher, et al.
Journal of Clinical Epidemiology|January 14, 2024
Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluationAshley M Hopkins, Natansh D Modi, Frank W Rockhold, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Frontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
Journal of the National Cancer Institute|September 28, 2017
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30Hanna Bandos, Joy Melnikow, Donna R Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera, Janice M Walshe, Douglas R Rosing, et al.
Cancer Medicine|May 2, 2013
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and TunisiaCatherine Schairer, Amr S Soliman, Sherif Omar, et al.
Pageof 21

Showing results (121-130 of 210) with videos related to

Sort By:
Pageof 21
Radiology|August 22, 2007
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experienceArpi Thukral, David M Thomasson, Catherine K Chow, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2022
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSandra M Swain, Antoinette R Tan, Luca Gianni, et al.
Journal of the National Cancer Institute|March 15, 2011
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCISIrene L Wapnir, James J Dignam, Bernard Fisher, et al.
Journal of Clinical Epidemiology|January 14, 2024
Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluationAshley M Hopkins, Natansh D Modi, Frank W Rockhold, et al.
The Lancet. Oncology|April 23, 2013
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studySandra M Swain, Sung-Bae Kim, Javier Cortés, et al.
Frontiers in Oncology|September 28, 2020
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast CancerKatia Khoury, Antoinette R Tan, Andrew Elliott, et al.
The New England Journal of Medicine|February 19, 2015
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerSandra M Swain, José Baselga, Sung-Bae Kim, et al.
Journal of the National Cancer Institute|September 28, 2017
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30Hanna Bandos, Joy Melnikow, Donna R Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera, Janice M Walshe, Douglas R Rosing, et al.
Cancer Medicine|May 2, 2013
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and TunisiaCatherine Schairer, Amr S Soliman, Sherif Omar, et al.
Pageof 21